Medical Devices Investors & VC Firms in United States

1104 firms in this list, with a median first check of $500K. 275 of them lead rounds. Generated from verified public data and updated continuously.

Fund	FoxScore	HQ	Invests	Stage	Check	CRM
AB Abingworth ASGLJPKV43 people	88🔒	London	GB	Seed–Late Stage	$15M – $30M	+ Add to CRM
TA Taiwania Capital HLDWHHIL49 people · Follows rounds	88🔒	Taipei	TW	Seed–Growth	—	+ Add to CRM
WO Women's Equity Lab JTSMSAAS35 people · Follows rounds	88🔒	Victoria	CA	Pre-Seed–Seed	$18K – $54K	+ Add to CRM
SU Supernova Invest CHFBPSRS41 people · Follows rounds	88🔒	Paris	FR	Seed–Growth	—	+ Add to CRM
FO Forbion GMSSAHDK25 people	88🔒	Naarden	NL	Pre-Seed–Late Stage	—	+ Add to CRM
ON OneVentures ABMDPKBS40 people · Leads rounds	88🔒	Sydney	AU	Seed–Late Stage	$3.3M – $13.2M	+ Add to CRM
HI Hitachi Ventures SGAGGSG(34 people · Leads rounds	88🔒	Munich	DE	Seed–Late Stage	—	+ Add to CRM
AD Advent Life Sciences DSKMRPSJ29 people	88🔒	London	GB	Seed–Growth	—	+ Add to CRM
NO Norrsken VC AFADDFLB26 people · Follows rounds	88🔒	Stockholm	SE	Seed–Series C	$1M – $10M	+ Add to CRM
PA Pacific Channel BOCSDRGP37 people	88🔒	Auckland	NZ	Pre-Seed–Series A	—	+ Add to CRM
DR DRI Healthcare AHDSAKAV42 people	88🔒	Toronto	CA	—	—	+ Add to CRM
DR Droia Ventures LVGGJNLD40 people · Follows rounds	88🔒	Luxembourg	LU	Pre-Seed–Series A	$540K	+ Add to CRM
AM aMoon MMTSYSYD34 people	88🔒	Ra'anana	IL	Seed–Late Stage	—	+ Add to CRM
UK UK Innovation & Science Seed Fund ALAMHMMW25 people · Leads rounds	88🔒	London	GB	Seed	$127K – $635K	+ Add to CRM
NI Nina Capital MSMGSADF26 people · Leads rounds	88🔒	Barcelona	ES	Pre-Seed–Series A	$200K – $1.5M	+ Add to CRM
JE Jeito Capital EGJFKPRT42 people · Leads rounds	88🔒	Paris	FR	Growth–Late Stage	—	+ Add to CRM
AD Adara Ventures AGLBNGAE25 people · Leads rounds	88🔒	Madrid	ES	Seed–Growth	$540K – $5.4M	+ Add to CRM
B4 B4 Capital LMMO2 people	88🔒	—		Seed–Late Stage	$10M – $50M	+ Add to CRM
VI Viola Credit IVAGCSEF44 people · Follows rounds	88🔒	Tel Aviv	IL	Growth–Late Stage	—	+ Add to CRM
NO Novartis Venture Fund AKBDFMFM22 people · Leads rounds	88🔒	Basel	CH	Seed–Growth	$5M – $25M	+ Add to CRM
VE Vertex Ventures China CCJYWLZX6 people · Follows rounds	88🔒	Singapore	SG	Pre-Seed–Series A	—	+ Add to CRM
K3 K3 Ventures MXSLTTYJ20 people	88🔒	Singapore	SG	Seed–Growth	—	+ Add to CRM
CO Co-Win Ventures 赵孙文林22 people · Leads rounds	88🔒	Suzhou	CN	Seed–Series A	—	+ Add to CRM
YS Ysios Capital CGJPJJJS26 people · Follows rounds	88🔒	San Sebastian	ES	Seed–Series C	$5.4M – $21.6M	+ Add to CRM

Abingworth

LondonSeed–Late Stage$15M – $30M

ASGLJPKV43 people

Taiwania Capital

TaipeiSeed–Growth

HLDWHHIL49 people

Women's Equity Lab

VictoriaPre-Seed–Seed$18K – $54K

JTSMSAAS35 people

Supernova Invest

ParisSeed–Growth

CHFBPSRS41 people

Forbion

NaardenPre-Seed–Late Stage

GMSSAHDK25 people

OneVentures

SydneySeed–Late Stage$3.3M – $13.2M

ABMDPKBS40 people

Hitachi Ventures

MunichSeed–Late Stage

SGAGGSG(34 people

Advent Life Sciences

LondonSeed–Growth

DSKMRPSJ29 people

Norrsken VC

StockholmSeed–Series C$1M – $10M

AFADDFLB26 people

Pacific Channel

AucklandPre-Seed–Series A

BOCSDRGP37 people

DRI Healthcare

Toronto

AHDSAKAV42 people

Droia Ventures

LuxembourgPre-Seed–Series A$540K

LVGGJNLD40 people

aMoon

Ra'ananaSeed–Late Stage

MMTSYSYD34 people

UK Innovation & Science Seed Fund

LondonSeed$127K – $635K

ALAMHMMW25 people

Nina Capital

BarcelonaPre-Seed–Series A$200K – $1.5M

MSMGSADF26 people

Jeito Capital

ParisGrowth–Late Stage

EGJFKPRT42 people

Adara Ventures

MadridSeed–Growth$540K – $5.4M

AGLBNGAE25 people

B4 Capital

Seed–Late Stage$10M – $50M

LMMO2 people

Viola Credit

Tel AvivGrowth–Late Stage

IVAGCSEF44 people

Novartis Venture Fund

BaselSeed–Growth$5M – $25M

AKBDFMFM22 people

Vertex Ventures China

SingaporePre-Seed–Series A

CCJYWLZX6 people

K3 Ventures

SingaporeSeed–Growth

MXSLTTYJ20 people

Co-Win Ventures

SuzhouSeed–Series A

赵孙文林22 people

Ysios Capital

San SebastianSeed–Series C$5.4M – $21.6M

CGJPJJJS26 people

Data sourced from public filings and firms' own websites — see our methodology.